Partner Publications

AfA Health Professional Newsletter

Aid for AIDS (AfA) was launched in May 1998 as a private sector HIV Disease Management programme providing a focused range of clinical interventions coupled with credible clinical support and on-going adherence management and patient support. The aim of the programme was to partner with healthcare providers and healthcare funders to optimize clinical outcomes by ensuring access to effective therapy and regular monitoring of outcomes and potential toxicity, thus limiting the frequency of treatment failure due to poor adherence or adverse effects. Sustained viral load suppression and immune recovery would reduce the risk of opportunistic infections and lead to improved survival. The programme has been successful and over 100,000 patients are currently receiving antiretroviral therapy with excellent clinical outcomes.

The AfA Clinical team can be contacted on 0800 227 700 or by email at Further information about AfA, the current treatment guidelines and back-copies of the quarterly newsletters can be found on the AfA website.


TB South

Published by i-base, a London-based treatment activitist organisation, the HIV Treatment Bulletin is a not-for-profit community journal that reviews the most important advances in the clinical management of HIV and access to treatment. HTB-South is focused on Southern Africa and disseminated through SAHCS.


  • Issue 49
    29 Mar 2019

    Tuberculosis Preventive Therapy for Adults; Undetectable = Untransmittable (U=U); Important drug-drug interactions with dolutegravir

  • Issue 48
    31 Jul 2018

    Potential safety issue affecting HIV+ women taking dolutegravir at the time of conception; New WHO guidelines for induction therapy in cryptococcal meningitis; Treatment of cytomegalovirus (CMV) retinitis; Isoniazid preventive therapy (IPT) in pregnancy

  • Issue 47
    28 Feb 2018

    Dolutegravir in pregnancy; Is there still a role for nevirapine?; The Xpert MTB/RIF Ultra: increased sensitivity for diagnosing HIV-associated TB with a small increase in false positive results; Treatment of multi-drug resistant gonorrhoea - what's in the pipeline?

  • Issue 46
    30 Sep 2017

    Severe efavirenz-induced ataxia and encephalopathy; Prolonged post-treatment virologic control in a South African HIV+ child after early antiretroviral therapy; The DAWNING trial.

  • Issue 45
    01 Mar 2017

    Early ART initiation as a factor in combating antibiotic resistance; Dolutegravir: not as monotherapy; BREATHER - Can HIV+ youth safely have a weekend off their antiretroviral medication?; Diagnosing "elite controllers"

  • Issue 44
    01 Oct 2016

    Rifabutin dosing with protease inhibitors; Drug-drug interactions involving second generation NNRTIs; Pure Red Cell Aplasia in HIV

  • Issue 43
    01 Jun 2016

    Dolutegravir: its use in adult patients Dolutegravir: its use in paediatric patients Drug-drug interactions between antiretrovirals and itraconazole Zika and HIV

  • Issue 42
    01 Feb 2016

    Do elite controllers need ART? Early infant diagnosis of HIV - shifting paradigms Lifelong ART should be offered to ALL HIV-infected patients regardless of CD4 count Pneumococcal vaccination in HIV-infected persons

  • Issue 41
    01 Sep 2015

    Probiotics and HIV Improved treatment outcomes in patients with XDR TB in South Africa HIV tests in children on ART Management of hyperlipidaemia in patients on protease inhibitors Cross-reactivity between darunavir and co-trimoxazole New 0199 tariff claiming process

  • Issue 40
    01 Jul 2015

    Rilpivirine (RPV) in pregnancy Is there a need for 6-monthly CD4 monitoring in patients with stable virological suppression on ART? Twitter for the busy Clinician - Opening up a world of HIV-related information The role of micronutrient supplementation in adults

  • Issue 39
    01 Mar 2015

    HIV-positive-to-HIV-positive renal transplantation Pre-exposure prophylaxis (PrEP): recent findings add to the evidence that it is effective as an HIV prevention tool Use of raltegravir in children Balancing risks and benefits in post exposure prophylaxis

  • Issue 38
    01 Nov 2014

    Abacavir-based regimens in patients with high viral loads Proton pump inhibitor, H2 receptor blocker and antacid drug interactions with atazanavir/ritonavir Update on the Mississippi child - a reality check Maraviroc A festive reflection

  • Issue 37
    01 Aug 2014

    The EARNEST trial: new evidence regarding efficacy of second line ART regimens New drug profile: rilpivirine The value of a psychological report in treatment failure Clinical Case Report - 35 year old male patient on a PMB Medical Scheme Option (Subject to State Protocols)

  • Vol 6 No 4
    02 Dec 2013

    HTB South

Copyrights ©2019: Southern African HIV Clinicians Society